Moderna has secured a $1.5 billion five-year loan from Ares to expand beyond vaccines into oncology and rare-disease treatments. The facility boosts financial flexibility, with $600 million drawn upfront and more available through 2028. The company targets 10% revenue growth in 2026, and MRNA shares rose 2% premarket.